Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.
Designed to provide broad exposure to the Health Care ETFs category of the market, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a smart beta exchange traded fund launched on 06/19/2006. What ...
The State Street SPDR S&P Pharmaceuticals ETF (XPH) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment ...
24/7 Wall St. on MSN
LABU could rip higher if biotech finally gets its long-awaited breakout
Quick Read Direxion Daily S&P Biotech Bull 3X Shares (LABU) delivered 235% returns over the past year versus 65% for the ...
Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...
Wed, February 18, 2026 at 4:58 PM UTC The ETF's return engine is straightforward: it captures the cash flows and appreciation potential of pharmaceutical businesses across the capitalization spectrum.
The current generation of deals, which is likely to involve AbbVie (NYSE: ABBV), Merck & Co Inc (NYSE: MRK), Bristol-Myers Squibb Co (NYSE: BMY), and Gilead Sciences Inc (NYSE: GILD), is focused on ...
Not every exchange-traded fund (ETF) worth owning trades at a premium. Some of the most structurally sound funds sit quietly below the radar, offering low costs, reliable income, or sector exposure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results